Government price setting policies may have different names and mechanisms, but all give bureaucrats control over our medicines and threaten access to treatments and cures. We need policies that will ensure Americans have access to the best treatments and address high out-of-pocket costs, but government price setting isn’t one of them.

**BINDING ARBITRATION FOR MEDICINES**

**INTERNATIONAL REFERENCE PRICING**

**MEDICARE “NEGOTIATION”**

**“AFFORDABILITY” BOARDS**

---

**GOVERNMENT PRICE SETTING POLICIES**

- **RELY ON POLITICIANS AND BUREAUCRATS**
  - to decide what diseases are worth investing in now and in the future.

- **GIVE BUREAUCRATS THE POWER**
  - to arbitrarily decide the value of our medicines—potentially discriminating against seniors, those with a disability and the chronically ill.

- **USE A POLITICAL PROCESS**
  - that inserts government and politicians in personal health decisions made by patients and their providers.

Learn more at PhRMA.org
Government Price Setting Unravels the Uniquely American Innovation Ecosystem and Could Shift Research and Development to Other Countries

American research leads the way in medical innovation, because we’ve built a system of collaboration and partnership, bringing together private sector scientists with academics and government researchers.

Government price setting would impact vital investments the biopharmaceutical industry makes in the research ecosystem. Now, more than ever, we need to support America’s collaborative research ecosystem, not unravel it.

Government Price Setting Puts Politicians in Charge

Prices of medicines in government-controlled markets reflect political trade-offs.

Government price setting means politicians arbitrarily decide that some patients and some diseases are worth more than others. We can’t let our medicines be subject to a political process and priorities that change with elections.

THERE ARE BETTER WAYS

Government price setting policies don’t address the root cause of the problem or patients’ biggest concern – rising out-of-pocket costs. There are better solutions to help patients save money that wouldn’t upend the health care system or jeopardize American innovation. Our goal should be lower out-of-pocket costs and improved access for patients rather than greater government control.

Learn more at PhRMA.org